Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

BioPharma Credit PLC

Financial Services GB BPCR

0.934GBX
0.01(1.52%)

Last update at 2026-03-10T15:41:00Z

Day Range

0.920.94
LowHigh

52 Week Range

0.730.97
LowHigh

Fundamentals

  • Previous Close 0.92
  • Market Cap105244.03M
  • Volume744158
  • P/E Ratio0.08
  • Dividend Yield7.48%
  • Revenue TTM154.66M
  • Revenue Per Share TTM0.13
  • Gross Profit TTM 154.66M
  • Diluted EPS TTM0.11

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax 122.18M 108.45M 182.31M 84.96M 89.14M
Minority interest - - - - -
Net income 122.18M 108.45M 182.31M 84.96M 89.14M
Selling general administrative 1.97M 1.86M 1.70M 2.86M 1.91M
Selling and marketing expenses 0.18M 0.17M 0.20M 0.20M 0.20M
Gross profit 124.46M 110.49M 184.25M 87.97M 91.35M
Reconciled depreciation - - - - -
Ebit 244.36M 216.91M - 84.98M 89.15M
Ebitda 122.18M 108.45M 182.31M 84.96M 89.14M
Depreciation and amortization -122.18000M -108.45700M - - -
Non operating income net other - - - - -
Operating income 122.18M 108.45M 182.31M 84.96M 89.14M
Other operating expenses 2.28M 51.23M 1.93M 3.01M 2.22M
Interest expense - - - 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 1.49M 4.32M 1.15M 3.13M 96.98M
Net interest income 1.49M 4.32M 1.15M 3.13M 96.98M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 108.45M - - -
Total revenue 124.46M 159.68M 184.25M 87.97M 91.35M
Total operating expenses 2.28M 2.04M 1.93M 3.01M 2.22M
Cost of revenue 25.57M 25.24M - - 18.65M
Total other income expense net 122.18M -0.00700M - - -
Discontinued operations - - - - -
Net income from continuing ops 122.18M 108.45M 182.31M 84.96M 89.14M
Net income applicable to common shares - - - 84.96M 89.14M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 1199.62M 1356.73M 1364.02M 1370.62M 1388.31M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets -31.79700M 0.09M - - -
Total liab 17.94M 15.87M 26.56M 6.34M 9.39M
Total stockholder equity 1181.68M 1340.86M 1337.45M 1363.72M 1378.91M
Deferred long term liab - - - - -
Other current liab 16.94M 15.87M 1.95M -6.34200M -
Common stock 13.74M 13.74M 13.74M 13.74M 13.74M
Capital stock 13.74M 13.74M 13.74M 13.74M 13.74M
Retained earnings 560.81M 720.00M - 742.85M 758.05M
Other liab - - - 0.56M -
Good will - - - - -
Other assets 1199.62M 48.85M - 1370.62M 1388.31M
Cash 5.62M 86.20M 120.53M 94.71M 193.27M
Cash and equivalents - - - - -
Total current liabilities 17.88M 15.87M - 6.34M 9.39M
Current deferred revenue - - - - -
Net debt -5.62000M -86.20200M -120.52700M -94.70900M -193.26900M
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity 607.12M 607.12M 1323.71M 1349.98M 1365.18M
Property plant equipment - - - - -
Total current assets 37.42M 155.37M 140.37M 104.72M 193.48M
Long term investments 1162.20M 1201.36M 1223.65M 1265.90M 1194.83M
Net tangible assets - - - 1363.72M 1378.91M
Short term investments - 48.85M - - -
Net receivables 31.80M 20.23M 19.84M 10.01M 0.21M
Long term debt - - - - -
Inventory - -0.09100M - - -
Accounts payable 0.95M 0.00000M - 6.34M -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 0.00000M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - 13.74M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -1162.20000M -1201.36200M -1223.65100M -1265.89800M -1194.83100M
Deferred long term asset charges - - - - -
Non current assets total 1162.20M 1201.36M 1223.65M 1265.90M 1194.83M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments 39.07M -1.65600M 48.19M -94.82100M -47.47200M
Change to liabilities - - 0.00000M -2.49200M -15.84200M
Total cashflows from investing activities 39.07M -1.65600M - -94.82100M -47.47200M
Net borrowings - - - - -
Total cash from financing activities -280.41500M -106.99300M -206.62400M -100.15700M -113.95700M
Change to operating activities - - - - -
Net income 122.18M 108.45M 182.31M 84.96M 89.14M
Change in cash -129.43300M 14.53M 25.82M -98.56000M -103.36900M
Begin period cash flow 135.05M 120.53M 94.71M 193.27M 296.64M
End period cash flow 5.62M 135.05M 120.53M 94.71M 193.27M
Total cash from operating activities 111.91M 123.18M 184.28M 96.44M 58.07M
Issuance of capital stock - - - - 0.00000M
Depreciation - - - - -
Other cashflows from investing activities - - - - -47.47200M
Dividends paid 174.66M 89.77M 156.54M 100.16M 113.90M
Change to inventory - - - - -
Change to account receivables -11.48000M -0.47900M - -9.80200M 16.00M
Sale purchase of stock -105.75300M -17.22000M -50.08700M 0.00000M -0.06000M
Other cashflows from financing activities - -1.65600M 48.19M -94.82100M -47.47200M
Change to netincome - - - 23.77M -31.22000M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -10.35800M -9.22000M 7.88M -12.29400M 0.16M
Stock based compensation - - - - -
Other non cash items 0.09M 23.95M -5.91800M 23.77M -31.22000M
Free cash flow 111.91M 123.18M 184.28M 96.44M 58.07M

Peer Comparison

Sector: Financial Services Industry: Asset Management

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x)
BPCR
BioPharma Credit PLC		 0.01 1.52% 0.93 0.08 - 6.80 0.93 8.49
BHMU
BH Macro Limited		 0.04 0.87% 4.62 0.06 - 52.34 0.71 4.88
III
3I Group PLC		 33.00 1.13% 2960.00 5.08 5.85 4.98 1.27
LGEN
Legal & General Group PLC		 9.60 3.84% 259.50 7.82 9.78 1.70 2.95 0.11
AMIF
Amicorp FS (UK) PLC		 - -% 1.02 1.02 - 7.59 17.62 7.43 52.55

Reports Covered

Stock Research & News

View All

Profile

BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. The company debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. BioPharma Credit PLC was incorporated in 2016 and is based in Leeds, the United Kingdom.

BioPharma Credit PLC

Central Square, Leeds, United Kingdom, LS1 4DL

Key Executives

Name Title Year Born
Mr. Pedro Gonzalez de Cosio Investment Mang. NA
Mr. Pablo Gerardo Legorreta Investment Mang. 1964
Mr. Martin G. Friedman Investment Mang. 1965
Mr. Pedro Gonzalez de Cosio Investment Manager NA
Mr. Pablo Legorreta Investment Manager 1963
Mr. Martin Friedman Investment Manager 1965

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.